AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17185020 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase at 0.5 mg/kg
Number of subjects: 12
Study 17185020 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase at 1.5 mg/kg
Number of subjects: 12
Study 17185020 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase (all doses)
Number of subjects: 12
Study 17185020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14660493 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breath (DB) intervention during methacholine-induced obstruction
Number of subjects: 18
Study 14660493 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breath (DB) intervention
Number of subjects: 18
Study 11209583 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape with embedded commercials
Number of subjects: 46
Study 11209583 — intervention group
Group type: COMPARATOR
Intervention: Videotape without commercials
Number of subjects: 46
Study 9846248 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 236
Study 9846248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 8122594 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of dipyridamole intravenously over 1 hour, starting immediately before the procedure (group 1)
Number of subjects: 977
Study 8122594 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole administered before the procedure (group 2)
Number of subjects: 977
Study 8122594 — intervention group
Group type: COMPARATOR
Intervention: No dipyridamole administered (group 3)
Number of subjects: 977
Study 2700432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 52
Study 2700432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 983794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g niceritrol given three times daily (1 g X 3)
Number of subjects: 18
Study 983794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g niceritrol given twice daily (1.5 g X 2)
Number of subjects: 18
Study 30372680 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month home-based physical activity program targeting 150 minutes/week of moderate physical activity
Number of subjects: 106
Study 30372680 — intervention group
Group type: COMPARATOR
Intervention: Control group continued with their usual lifestyle
Number of subjects: 106
Study 28199805 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 150
Study 28199805 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 150
Study 28199805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 150
Study 28199805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 150
Study 28199805 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 150
Study 25698766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Number of subjects: 50
Study 25698766 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 50
Study 22822936 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal reminders
Number of subjects: 0
Study 21512825 — intervention group
Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes (GA versus GG)
Number of subjects: 1307
Study 21512825 — intervention group
Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes (GA/AA versus GG)
Number of subjects: 1307
Study 21512825 — intervention group
Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes among those aged ≥ 45 years
Number of subjects: 1307
Study 21512825 — intervention group
Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes among male subjects
Number of subjects: 1307
Study 21512825 — intervention group
Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes among patients with glioblastoma
Number of subjects: 1307
Study 19487274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic (US) scoring system of salivary glands (0-48 scale)
Number of subjects: 135
Study 19487274 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphy (0-12 scale)
Number of subjects: 135
Study 19487274 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary gland biopsy
Number of subjects: 135
Study 19487274 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographic (US) scoring system
Number of subjects: 135
Study 17156174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (30 mg or 60 mg tablets)
Number of subjects: 235
Study 17156174 — intervention group
Group type: COMPARATOR
Intervention: Methadone mixture (1 mg/ml)
Number of subjects: 235
Study 17156174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine
Number of subjects: 235
Study 17156174 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 235
Study 14701900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff on bare arm
Number of subjects: 201
Study 14701900 — intervention group
Group type: COMPARATOR
Intervention: Cuff over the sleeve
Number of subjects: 201
Study 14701900 — intervention group
Group type: COMPARATOR
Intervention: Cuff below the rolled-up sleeve
Number of subjects: 201
Study 14701900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff on bare arm in hypertensive subjects
Number of subjects: 201
Study 10699069 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy alone (n = 348)
Number of subjects: 694
Study 10699069 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with postoperative radiotherapy (n = 346)
Number of subjects: 694
Study 10699069 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus LV chemotherapy in male patients (n = 200)
Number of subjects: 694
Study 10699069 — intervention group
Group type: COMPARATOR
Intervention: MOF chemotherapy in male patients (n = 207)
Number of subjects: 694
Study 9116271 — intervention group
Group type: EXPERIMENTAL
Intervention: Centroblastic lymphoma
Number of subjects: 219
Study 9116271 — intervention group
Group type: EXPERIMENTAL
Intervention: B-immunoblastic lymphoma
Number of subjects: 219
Study 9116271 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 219
Study 9116271 — intervention group
Group type: COMPARATOR
Intervention: Relapse-free survival
Number of subjects: 219
Study 8104017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 15
Study 8104017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 15
Study 8104017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 30 mg
Number of subjects: 15
Study 8104017 — intervention group
Group type: COMPARATOR
Intervention: Triprolidine 10 mg
Number of subjects: 15
Study 3725965 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexon (polyglycolic acid)
Number of subjects: 21
Study 3725965 — intervention group
Group type: COMPARATOR
Intervention: Prolene (polypropylene)
Number of subjects: 21
Study 30215735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 8
Study 30053896 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06438179/GP1111 (3 mg/kg intravenous at weeks 0, 2, and 6, then every 8 weeks; dose escalation to 5 mg/kg allowed starting at week 14)
Number of subjects: 650
Study 30053896 — intervention group
Group type: COMPARATOR
Intervention: Infliximab-EU (3 mg/kg intravenous at weeks 0, 2, and 6, then every 8 weeks; dose escalation to 5 mg/kg allowed starting at week 14)
Number of subjects: 650
Study 30053896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (PF-06438179/GP1111 and infliximab-EU)
Number of subjects: 650
Study 26843085 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplement (Multicentrum, Pfizer, 1 tablet/day) during 3 months
Number of subjects: 80
Study 26843085 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplement (Multicentrum, Pfizer, 1 tablet/day) during 12 months
Number of subjects: 80
Study 24451619 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral conditions
Number of subjects: 15
Study 24451619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot conditions
Number of subjects: 15
Study 24451619 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐ or lower‐body exercise (unloaded or loaded)
Number of subjects: 15
Study 24451619 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper‐body work
Number of subjects: 15
Study 24451619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hyperthermia
Number of subjects: 15
Study 22429187 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% hempseed oil (HO)
Number of subjects: 48
Study 22429187 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% hempseed oil (HO)
Number of subjects: 48
Study 22429187 — intervention group
Group type: COMPARATOR
Intervention: Control (0% hemp)
Number of subjects: 48
Study 22429187 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% hempseed (HS)
Number of subjects: 48
Study 20224262 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 instillations of 1% silver nitrate solution
Number of subjects: 59
Study 20224262 — intervention group
Group type: COMPARATOR
Intervention: 9 instillations of 1% silver nitrate solution
Number of subjects: 59
Study 17391132 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg b.i.d.
Number of subjects: 18
Study 17391132 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 1000 mg b.i.d.
Number of subjects: 18
Study 17391132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EC-MPS and MMF
Number of subjects: 18
Study 12781883 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintimammography with (99m)Technetium‐Sestamibi
Number of subjects: 1734
Study 10683057 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d of androstenedione
Number of subjects: 42
Study 10683057 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/d of androstenedione
Number of subjects: 42
Study 10683057 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/d of androstenedione (control)
Number of subjects: 42
Study 9313385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient intake and vitamin levels assessment
Number of subjects: 79
Study 9313385 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in body mass index over time
Number of subjects: 79
Study 8364949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg intramuscularly every 3 to 6 hours as needed, followed by 10 mg every 4 to 6 hours)
Number of subjects: 210
Study 8364949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 210
Study 8364949 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (100 mg intramuscularly every 3 to 6 hours as needed, followed by acetaminophen/codeine (600 mg/60 mg) orally every 4 to 6 hours)
Number of subjects: 210
Study 8364949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac and Meperidine
Number of subjects: 210
Study 2877383 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone treatment
Number of subjects: 99
Study 2877383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 30094160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 33
Study 30094160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 26984236 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 294
Study 24434680 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetration enhancers
Number of subjects: 60
Study 24434680 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaMembranSysteme® (DMS®)
Number of subjects: 60
Study 22387936 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h food diary (DIET‐24)
Number of subjects: 191
Study 22387936 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 191
Study 20584668 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg intravenously, repeated at 24 and 48 hours post-operation
Number of subjects: 80
Study 20584668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline equivalent volume)
Number of subjects: 80
Study 19189813 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient psychodynamic psychotherapy based on the Conversational Model for 2 years
Number of subjects: 2
Study 19189813 — intervention group
Group type: COMPARATOR
Intervention: Outpatient psychodynamic psychotherapy based on the Conversational Model for 1 year
Number of subjects: 2
Study 15691793 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmakinetic vaporesection of the prostate (PKVP)
Number of subjects: 60
Study 15691793 — intervention group
Group type: COMPARATOR
Intervention: Conventional transurethral resection of the prostate (TURP)
Number of subjects: 60
Study 12753536 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 142
Study 12753536 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DXM)
Number of subjects: 142
Study 10391601 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (17.5 mg)
Number of subjects: 24
Study 10391601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.6 mg) and intrathecal bupivacaine (17.5 mg)
Number of subjects: 24
Study 8699981 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A detergent
Number of subjects: 8
Study 8699981 — intervention group
Group type: EXPERIMENTAL
Intervention: Type C detergent
Number of subjects: 8
Study 1814770 — intervention group
Group type: EXPERIMENTAL
Intervention: Light‐ and chemically‐cured glass‐ionomer‐based restorations
Number of subjects: 100
Study 1814770 — intervention group
Group type: COMPARATOR
Intervention: Cavities both etched and bonded
Number of subjects: 100
Study 1814770 — intervention group
Group type: COMPARATOR
Intervention: Cavities restored without enamel etching or bonding system
Number of subjects: 100
Study 6658432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA) at 25 mg/kg body weight
Number of subjects: 113
Study 6658432 — intervention group
Group type: COMPARATOR
Intervention: Ethambutol (EMB) at 25 mg/kg body weight
Number of subjects: 113
Study 30946709 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP measurements during telemedicine screening
Number of subjects: 902
Study 29944706 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing (DSW)
Number of subjects: 24
Study 29944706 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing (DSW) and daily activity tracking (DAT)
Number of subjects: 24
Study 29944706 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily activity tracking (DAT)
Number of subjects: 24
Study 26861865 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPSYS system (intervention group)
Number of subjects: 94
Study 26861865 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 94
Study 24946564 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedics lotion fumigation treatment (treatment group)
Number of subjects: 60
Study 24946564 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate intra-articular injection (control group)
Number of subjects: 60
Study 24946564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (treatment and control)
Number of subjects: 60
Study 23575046 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive fentanyl 25 μg (0.5 ml) prior to fentanyl 125 μg (2.5 ml)
Number of subjects: 150
Study 23575046 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive fentanyl 25 μg (0.5 ml) prior to fentanyl 150 μg (3 ml)
Number of subjects: 150
Study 23575046 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (0.5 ml) prior to fentanyl 150 μg (3 ml)
Number of subjects: 150
Study 19721169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular injection of 8 ml of 2% lidocaine
Number of subjects: 80
Study 19721169 — intervention group
Group type: COMPARATOR
Intervention: No intracapsular anesthesia (control group)
Number of subjects: 80
Study 17961836 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline bolus (group NSB)
Number of subjects: 100
Study 17961836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate bolus (group RLB)
Number of subjects: 100
Study 17961836 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline infusion (group NSI)
Number of subjects: 100
Study 17961836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate infusion (group RLI)
Number of subjects: 100
Study 17961836 — intervention group
Group type: COMPARATOR
Intervention: Control group (no washout fluid)
Number of subjects: 100
Study 14504772 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 12
Study 14504772 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 12
Study 10683101 — intervention group
Group type: EXPERIMENTAL
Intervention: Energetically optimal cadence (70 +/- 4.5 rpm)
Number of subjects: 10
Study 10683101 — intervention group
Group type: EXPERIMENTAL
Intervention: Freely-chosen cadence (83 +/- 6.9 rpm)
Number of subjects: 10
Study 10683101 — intervention group
Group type: EXPERIMENTAL
Intervention: Energetically optimal cadence (86 +/- 6.2 rpm)
Number of subjects: 10
Study 9025819 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training with true feedback (TFB)
Number of subjects: 18
Study 9025819 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training with false feedback (FFB)
Number of subjects: 18
Study 9025819 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group - CTL)
Number of subjects: 18
Study 1497157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 31
Study 1497157 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (75 mg)
Number of subjects: 31
Study 6206687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol (300 mg I/ml)
Number of subjects: 40
Study 6206687 — intervention group
Group type: COMPARATOR
Intervention: Metrizamide (300 mg I/ml)
Number of subjects: 40
Study 6206687 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 40
Study 6206687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol and Metrizamide
Number of subjects: 40
Study 31302514 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention
Number of subjects: 158
Study 27489241 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-NKG2D (2 mg/kg, single subcutaneous dose)
Number of subjects: 78
Study 27489241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 26241597 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction therapy (n=58)
Number of subjects: 116
Study 26241597 — intervention group
Group type: COMPARATOR
Intervention: Present-centered group therapy (n=58)
Number of subjects: 116
Study 23508680 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial and/or pharmacotherapy (sertraline)
Number of subjects: 166
Study 21644308 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive point moxibustion
Number of subjects: 60
Study 21644308 — intervention group
Group type: COMPARATOR
Intervention: Gaitianli (Oyster Shell and Calcium Carbonate Chewable) tablets
Number of subjects: 60
Study 18623168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement with 6 diagnostic categories
Number of subjects: 90
Study 18623168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement with final diagnostic categories (microscopic colitis vs nonmicroscopic colitis)
Number of subjects: 90
Study 18623168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean intraobserver agreement with 6 diagnostic categories
Number of subjects: 90
Study 18623168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean intraobserver agreement with final diagnostic categories (microscopic colitis vs nonmicroscopic colitis)
Number of subjects: 90
Study 16674625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorges laryngoscope
Number of subjects: 20
Study 16674625 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 20
Study 16674625 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study 16109591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 29
Study 16109591 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 29
Study 10232502 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg, increased to 160 mg after 4 weeks)
Number of subjects: 100
Study 10232502 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg, increased to 100 mg after 4 weeks)
Number of subjects: 100
Study 10232502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8674154 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IV dose of dolasetron (1.8 mg/kg)
Number of subjects: 55
Study 8674154 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose regimen of dolasetron (0.6 mg/kg each, total 1.8 mg/kg)
Number of subjects: 55
Study 8674154 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 55
Study 1855018 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid with distension
Number of subjects: 47
Study 1855018 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid only
Number of subjects: 47
Study 1855018 — intervention group
Group type: COMPARATOR
Intervention: Distension only
Number of subjects: 47
Study 6411441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (7 micrograms/kg . min)
Number of subjects: 12
Study 6411441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (7 micrograms/kg . min) + Nitroglycerin (1.5-3.0 mg/h)
Number of subjects: 12
Study 6411441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (3.0-6.0 mg/h)
Number of subjects: 12
Study 6411441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (increased dose)
Number of subjects: 12
Study 31640881 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster-based intervention displaying an image of eyes and blood culture sampling guidelines
Number of subjects: 31
Study 31640881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31